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SUMMARY
We present the frequency and the nature of contact incidents of the Serotine bat, Eptesicus
serotinus, with humans and with companion animals (speciﬁcally cats and dogs), in The
Netherlands between 2000 and 2005. Out of 17 bats in bite contact with humans, ﬁve tested
positive for European bat lyssavirus (EBLV) type 1a. Cats had the most numerous contacts with
bats (49 times) but a relatively low number of these bats were EBLV positive (six times). We
estimated that the average incidence of human bat rabies infection might be between once per
year and once per 700 years, depending mainly on the number of infectious viral particles in bat
saliva. The risk of bat rabies is higher between April and October, and in the northern half of the
country. This is the ﬁrst study in Europe describing the risk of human bat rabies after bat contact
incidents.
INTRODUCTION
European bat lyssaviruses (EBLVs), family Rhab-
doviridae, genus Lyssavirus, are most probably trans-
mitted to humans by biting. In The Netherlands, the
reservoirs of EBLV-1 are found to be the Serotine bat,
Eptesicus serotinus, and for EBLV-2 the pond bat,
Myotis dasycneme, but the Serotine bat is by far
the most important reservoir [1]. The prevalence in
The Netherlands of EBLV-1 ﬂuctuates around 20%
of the submitted Serotine bats [1]. In the past
decades, ﬁve single fatal cases of bat rabies in humans
caused by EBLV have been reported from respectively
Ukraine (1977, 2002), Russia (1985), Finland (1985),
and Scotland (2002) [2–4].
Among the native mammal species in The
Netherlands involved in biting humans, bats are the
leading cause for administering post-exposure rabies
vaccinations. Between 1987 and 1992, 174 people in
The Netherlands were vaccinated after suspected
contact with native bats [5] and between 1997 and
2003, 148 people were vaccinated [6]. In Denmark, 10
individuals received prophylactic treatment for poss-
ible exposure to bat rabies in 2003 [7].
Rabid bats can transmit the virus to domestic as
well as to wild non-chiropteran mammals, but records
of bat rabies in non-chiropteran mammal species in
Europe are rare. Thus far, transmission to ﬁve sheep
in Denmark [8] and to a Stone marten, Martes foina,
in Germany [9] has been reported. From a survey of
domestic cats in Denmark it was estimated that 1–3%
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of cats were EBLV seropositive [10]. Domestic cats
do, indeed, prey on numerous small animals, in-
cluding bats [11]. Although probably rare, indirect
transmission of EBLV to humans via domestic and
wild mammals might be possible.
The risk for humans contracting bat rabies after
any contact with a rabid bat depends partly on the
frequency and nature of the exposure to infected bats.
For the purpose of assessing the risk of bat rabies to
humans, we report the frequency and the nature of
bat incidents in humans, as well as in cats and dogs.
In addition, a mathematical model is developed to
evaluate the dose-dependent risk of human bat rabies
infection. Although we identiﬁed that essential infor-
mation is still lacking, this study was undertaken to
show a concept of how to assess the risk of bat rabies
in humans after exposure by rabid bats.
MATERIALS AND METHODS
Bat specimens
Passive surveillance of lyssaviruses in bats has been
undertaken in The Netherlands since 1984. Grounded
bats that were unable to ﬂy and bats reported to have
been in contact with humans and/or pets were sub-
mitted to the Central Institute for Animal Diseases
Control (CIDC–Lelystad) for detection of lyssavirus
antigen. This surveillance was carried out nationwide
from 1987 to 1994 but thereafter testing for EBLV
was largely restricted to suspected rabid bats, and bats
involved in contact with humans and/or pets. Brain
tissues were collected from all bats submitted between
1984 and 2005. Over 100 specimens from diﬀerent bat
species were normally tested for EBLV annually.
Thirty bats that were diagnosed positive for EBLV by
polymerase chain reaction (PCR) and ﬂuorescent
antibody test (FAT) in a 3-year period were used to
determine the presence of the virus in salivary glands
and neck skin.
Detection of lyssavirus
Bats were tested for EBLV by standard FAT as de-
scribed by Dean et al. [12] with minor modiﬁcations,
using polyclonal ﬂuorescein isothiocyanate-labelled
rabbit anti-rabies nucleocapsid IgG (Diagnostics
Pasteur, Marnes-la-Coquette, France). Mice were in-
oculated intracerebrally with clariﬁed brain tissue
suspensions originating from either an experimentally
infected cat (genotype 1) or an infected Serotine bat
from the ﬁeld (genotype 5). Mice were killed after
clinical symptoms appeared. Brain tissue smears of
these mice were used as positive controls in the FAT.
Duplicate smears were carefully and completely
checked for ﬂuorescence. For ampliﬁcation of EBLV-
speciﬁc RNA, tissue samples (3 mm3) were placed in
0.5 ml RNA extraction buﬀer. The RNA extraction
was performed using TRIzol. TRIzol (1 ml) was ad-
ded to the tissue sample and RNA extraction was
performed according the manufacturer’s protocol
(TRIzol, Invitrogen Life Technologies, Merelbeke,
Belgium). Reverse transcription (RT) and PCR am-
pliﬁcation were performed as described by Heaton
et al. [13] followed by Southern blot hybridizations of
RT–PCR products as described by Van der Poel et al.
[14].
Geographical analysis
The species, gender, and age of each bat were ident-
iﬁed by external body features and, together with the
determined ﬁnding date and location (5r5 km grid),
inserted in a database. The database consisting of a
total of 1271 records of the Serotine bat was used
for geographical analysis. For Serotine bats collected
in 2000–2005, the nature of contacts with humans
and animals was also determined and added to the
database for contact analysis. The locations of col-
lected bats were visualized using ArcGIS 9 (ESRI,
Redlands, CA, USA). The population density was
calculated from 1219 Serotine bat records for the
period 1984–2004 [1] with the program Spatial
Analyst (ESRI) using a kernel density and a search
radius equal to 30 km.
Risk of EBLV
We describe the number of humans bitten by any
Serotine bat in a given year as a stochastic process by
using a Poisson distribution with the average number
of biting incidents equal to l. Since we assume that
the majority of bite incidents do not lead to rabid
disease, we denote by the symbol p the probability of
developing human bat rabies upon being bitten by a
Serotine bat. In this situation, the number of human
bat rabies cases when a random number of biting
incidents occurs (determined by the Poisson distri-
bution with the rate l) is Poisson distributed with the
new rate lp, i.e. it is a Poisson mixture of a binomial
distribution [15].
The probability of developing rabies upon being
bitten by a Serotine bat depends on the person’s
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susceptibility to the virus and the number of infec-
tious EBLV viral particles transmitted into the
body through the biting wound. We assume that a
single viral particle can, although not necessarily,
cause human rabies with a small probability r, which
can be deduced from experimental infection with
EBLV-1a in mice [16] using a single-hit dose–response
model [17, 18]. The single-hit dose–response model
is often applied for ingested infectious material,
i.e. foodborne pathogens, but its mathematical
derivation does not depend on the speciﬁc mode of
entrance into the host body and therefore the theory
can be applied to infection caused by the bite of an
infected Serotine bat. The number of virus particles
in the saliva is expected to vary between individual
Serotine bats ; some Serotine bats might not excrete
the virus at all, others do only in low numbers and
some in higher numbers. We denote by the symbol
f(i) the likelihood that the number of the viruses
excreted in a unit volume (e.g. 1 ml) of the bat’s
saliva is equal to i. When i virus particles in a unit
volume are transmitted through the open wound,
the probability of at least one virus particle inﬂicting
the disease in the victim is equal to 1 – (1 – r)i.
Because i can be any non-negative integer we sum this
quantity weighted by the likelihood f(i) to obtain








Because no experimental data is available to estimate
f(i), we consider the best and the worst cases. The risk
of bat rabies is the highest if all infected bats excrete a
large number of the viruses in excess of human LD50
[=rx1 ln (2)]. Denoting by k a number in excess of
human LD50, the risk of bat rabies approaches the











Assuming all infected bats excrete only one virus
particle, we would obtain a low estimate of risk:
p= 1x(1xr)1
 
f(1)=rf(1)=r 1xf(0)½ : (2)
Seasonal change in the prevalence
We describe the number of rabid bats by the binomial
distribution with the prevalence that can either be a
constant or be speciﬁc to summer and winter months.
The beneﬁt of assuming season speciﬁc prevalence is
tested by the likelihood ratio test. The deviance (twice
the diﬀerence of log-likelihood values) is incorporated
into the x2 distribution with 1 degree of freedom to
calculate the P value.
RESULTS
Contact incidents
Between 2000–2005 encounter of humans and pets
with Serotine bats varied in frequency and contact
type (Table). In this period 17 humans were bitten by
bats, 15 touched bats and one person had a contact of
unknown nature. Five of the 17 bats that bit people
were EBLV positive (29%). EBLV was detected in 3/
15 bats involved in only hand contact (20%) as well
as in a single bat that had a contact of unknown
nature. Overall prevalence of EBLV in Serotine bats
coming into close contact with humans is 27% (9/33)
Table. Incidents and contact types with Serotine bats in 2000–2005
Nature of contact Rabid Not Total
Prevalence
(%)
Bat bites in humans 5 12 17 29
Human hand contact with bats 3 12 15 20
Contact of unknown nature with humans 1 0 1 100
Possible contact with cats 4 12 16 25
Contact of unknown nature with cats 2 31 33 6
Possible contact with dogs 0 1 1 0
Contact of unknown nature with dogs 1 1 2 50
No contact with humans, cats, or dogs 16 13 29 55
Unknown 7 44 51 14
Total 39 126 165 24
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consisting of biting (5/17), hand contact (3/15), and a
contact of unknown nature (1/1) (Table). Cats had the
most frequent contacts with bats (49 times including
suspected contacts ; Table). However, only six (12%)
of these bats were shown to be positive for EBLV.
Contacts of dogs with bats were reported three
times only. Serotine bats that did not have contact
with humans or pets were more likely to be EBLV
positive (16/29=55%). Bat incidents with humans
and with cats were reported nationwide but incidents
with EBLV-positive bats were clustered in the north-
ern half of the country (Fig.).
Seasonal prevalence
Bat contact incidents were reported in all seasons
but more often in summer months when bats are ex-
hibiting more ‘out-roost ’ activity than during the
hibernation period. The total monthly reports be-
tween 2000 and 2005 amounted to 165 incidents with
highest number of reports in July and August. In this
period a total of 39 bats were found to be rabies
positive with again the highest numbers in July
and August (8/30 and 9/38 positives, respectively).
Regardless of contact type, the chance of contacting
EBLV-positive Serotine bats between April and
October (38/134=28%) was signiﬁcantly higher than
during the hibernation period between November and
March (1/31=3%, P=0.998).
Presence of EBLV in diﬀerent body parts
EBLV was present in the neck skin of 20/30 brain
tissue-positive bats (67%) and in medulla oblongata
in 27/28 brain tissue-positive bats (96%). Most
importantly for the risk of bat rabies by biting, EBLV
was present in the salivary glands of 22/30 brain
tissue-positive bats (73%). In order not to underesti-
mate the risk of bat rabies, we assume that all brain
tissue-positive Serotine bats do excrete one or more
EBLV particle in the saliva.
Risk of human bat rabies
A total of 17 bats that bit humans were identiﬁed in
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Fig. Bat contact incidents 2000–2005. (a) Incidents of human individuals bitten by Serotine bats or having touched Serotine
bats by hand are indicated by solid circles ($, EBLV negative) or by open triangles (, EBLV positive). The density of
EBLV-positive Serotine bats in the environment is indicated by the grey shading; darker shading represents higher density.
(b) Incidents of cats contacting or suspected of contacting Serotine bats are indicated by solid circles ($, EBLV negative) or
by open triangles (, EBLV positive).
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bites reported in each year are 1, 5, 3, 1, 3, and 4,
ordered chronologically from 2000 to 2005. The
mean number of reported bites per year (2.8) is ap-
proximately equal to the variance (2.6), justifying our
assumption that the number of reported bites per
year is Poisson distributed. According to national
statistics [19], a total of 16 305 526 individuals
lived in The Netherlands in 2005. Thus the average
exposure rate based upon the reported biting
incidents is 2.8 bites per year (l) per population of 16
million. We estimate the probability that an infec-
tious EBLV particle inﬂicts human rabies (r) based
on experimental EBLV infections using mice [16].
In ﬁve mice intramuscularly injected with 102
.5
f.f.u. (foci-forming units) of EBLV-1a, two mice
died. With 104
.5 f.f.u., 5/5 mice died. Using a single-
hit dose–response model [17, 18] the maximum-
likelihood estimate of the probability r is equal to
1.6r10x3 per injected virus. To estimate f(i) the
likelihood that the number of EBLV excreted in
the saliva of individual Serotine bats is equal to i,
we note that 12/17 Serotine bats that bit humans
were EBLV negative. Thus f(0)=12/17=0.7. Un-
fortunately it is not known what exactly the number
of EBLV particles was in the ﬁve EBLV-positive
Serotine bats that did bite humans. In addition, there
is no information available, even in the literature,
regarding the concentration of EBLV in the saliva of
Serotine bats.
To make a maximum estimate for the risk, we as-
sume that all ﬁve bats were excreting a large number
of EBLV viruses in excess of human LD50. Then
by equation (1) the probability of acquiring human
bat rabies upon being bitten by a Serotine bat is
p=1xf(0)=1x0.7=0.3. Thus, the estimated risk of
human bat rabies infection is lp=2.8r0.3B0.8 per
year on average. The number of human bat rabies
cases in a given year varies according to a Poisson
distribution with the rate 0.8 per year. In a 14-year
period, one would expect 6 years of no human bat
rabies cases, 5 years of one case, 2 years of two cases,
and 1 year of three or four cases. More than ﬁve
human cases are unlikely to occur. Thus it is estimated
that as a mean about one case per year would occur
when there is no post-exposure prophylaxis. This is
the worst-case scenario.
If the ﬁve EBLV-positive bats transmitted only one
EBLV particle, we would obtain a low estimate of
risk. Using equation (2) we obtain
p=r 1xf(0)½ =1:6r10x3[1x0:7]  5r10x4:
That means human bat rabies might occur at the rate
equal to lpB1.4r10x3 per year, equivalent to once
in 700 years on average in The Netherlands, a country
of 16 million residents.
DISCUSSION
The estimated risk of EBLV from a bat biting based
upon the reported contacts with bats and the EBLV
prevalence among the bats involved in the contact
incidents still ranges widely between 1 per year and
1 per 700 years in a population of 16 million residents.
In taking a systematic approach to the public health
implication of EBLV, this study identiﬁed the most
important information gap: to reduce uncertainty in
the estimated risk of rabies infection of Serotine bat
origin, a quantiﬁcation of EBLV in the saliva of these
bats is needed. Active surveillance in Serotine bats [20]
or experimental EBLV infection in Serotine bats
could ﬁll the information gap. EBLV is generally
believed to be excreted in the saliva in a low concen-
tration, but only limited data on this subject are
available [21, 22]. If this is correct, the risk of bat
rabies following a bite by a rabid bat would still be
present but negligibly small [23]. However, if low
amounts of EBLV are shed by saliva, it might be dif-
ﬁcult to explain how EBLV can circulate in Serotine
bat populations, unless one considers a vertical
transmission or other routes that do not involve
biting, e.g. infection of the mucous membrane via
aerosols or by licking. In an experimental infection
vampire bats excreted y103 rabies virus particles
(genotype 1) per ml of saliva on only one occasion and
remained apparently healthy until the experiment
ended on the 710th day [24]. Relevance of this study
to our study is however limited because the rabies
virus genotype and the bat species used to perform
the experiment were diﬀerent and because extremely
high viral doses were used in that experimental in-
fection. Nonetheless it cannot be excluded that
rabid Serotine bats may excrete a high concentration
of EBLV. A total of 103 EBLV is suﬃcient to cause
neurological disorder and death in about a half of
the mice by the intramuscular route [16]. It might be
clear that for the purpose of risk assessment, more
quantitative information is needed on the number of
EBLV viral particles transmitted by saliva or other
body ﬂuids.
The Serotine bat is relatively common in The
Netherlands and can be found throughout the whole
country. It lives mainly alongside humans in cavity
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walls of houses and other buildings. The population
density is the highest in the northern part of the
country, especially in the north-western part. In
the southern part it is present but in low numbers
[25]. This suggests that the population density in the
southern part is below the critical density at which
EBLV is able to persist.
Records of contacts between cats and EBLV-
positive bats are relatively low. The reason why most
cats have no contact with EBLV-positive bats is yet
to be resolved, but from some observations we know
that rabid bats sometimes screech against approach-
ing subjects or emitted sounds, and this may deter
cats from catching such bats. In accordance with the
observed low contact rate, cats submitted for rabies
diagnosis in The Netherlands thus far proved to be
EBLV negative.
In The Netherlands, EBLV-1 (genotype 5) seems
to be endemic in the Serotine bat and human bite
incidents regularly occur. Therefore the public
health risk of bat rabies cannot be ignored. More
quantitative data on the number of infectious EBLV
particles in the saliva of rabid bats are needed.
However, our results suggest that, especially in the
period between April and October, humans and
companion animals in the northern part of the
country have a higher risk of encountering rabid bats
than those in the southern part.
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